Industries > Pharma > Asthma and COPD Therapies Market Forecast 2014-2024
Back to Pharma Reports

Asthma and COPD Therapies Market Forecast 2014-2024

Opportunities for Leading Companies

PUBLISHED: 27 October 2014
PAGES: 335
PRODUCT CODE: PHA0010
SUBMARKET: Therapeutic Drugs

Clear
WOOCS 2.2.1
DOWNLOAD FREE SAMPLE
SKU: PHA0010 Categories: ,

Asthma and COPD therapies – new study showing you trends, R&D progress, and predicted revenues
Where’s the asthma and COPD therapies market heading? Visiongain’s brand new report shows you potential revenues to 2024, assessing data, trends, opportunities and prospects there.

Our 335-page report provides 264 tables, charts, and graphs. Discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market and national level. You will see financial results, interviews, trends, opportunities, and revenue predictions. Much opportunity remains in this growing pharma market.

Forecasts from 2014-2024 and other analyses show you commercial prospects
Besides revenue forecasting to 2024, our new study provides you with recent results, growth rates, and market shares. There you find original analyses, with business outlooks and developments. Discover qualitative analyses (including SWOT and Porter’s Five Forces Analysis), company profiles and commercial developments. Read the full transcripts of six exclusive expert opinion interviews from industry specialists informing your understanding and allowing you to assess prospects for investments and sales, including:
• Clive Page, Professor of Pharmacology, King's College London
• Monica Fletcher, Chief Executive, Education for Health
• Daphne Tsitoura, Senior Medical Director, GSK
• Barbara Yawn, Director of Research, Olmsted Medical Center
• Ahmed Wagih, Product Manager, Respiratory Franchise, GSK

Discover sales predictions for the world market and submarkets
Along with revenue prediction for the overall world market, you see forecasts to 2024 for the following submarkets:
• Bronchodilator monotherapy – SABAs, LABAs, anticholinergic drugs
• Anti-inflammatory drugs – inhaled corticosteroids, anti-leukotrienes, monoclonal antibodies
• Combination drugs.

Our investigation discusses what stimulates and restrains business. You find dynamics of the industry and assess its potential sales, seeing agents likely to achieve the most success.

See revenue forecasts for products
How will leading drugs and promising products currently in development perform to 2024 at world level? Our study forecasts sales of 27 products, including these:
• Advair/Seretide
• Atrovent
• Combivent
• Flixotide/Flovent
• Pulmicort
• Singulair
• Spiriva
• Symbicort
• Ventolin
• Xolair
• Reslizumab
• Mepolizumab

Discover how high revenues can go. You see what's happening, understanding trends, challenges and opportunities.

Our analysis also breaks the main world forecast into geographical markets.

What are the prospects in the leading regions and countries?
In addition to analyses of the overall world market, you discover individual revenue forecasts for 12 national markets to 2024:
• US
• Japan
• China
• Germany
• France
• UK
• Italy
• Spain
• India
• Brazil
• Russia
• Mexico
• Rest of the World

There will be growth in established pharma markets and in developing countries. Our analyses show that India, Russia, China and Mexico, in particular, will continue to achieve high revenue growth to 2024. Developments worldwide in product approval and pricing will influence the market.

Leading companies and potential for market growth
Overall world revenue for asthma and COPD therapies will reach $33.1bn in 2014, our work forecasts. We predict slow revenue growth from 2014 to 2018 and faster growth from 2018 to 2024. Rising demand for asthma and COPD drugs, expanding healthcare coverage, new drugs for severe asthma and a strong R&D pipeline will increase sales to 2024.

Our work shows you what organisations hold greatest potential. See profiles of 7 leading companies, including these:
• AstraZeneca
• Boehringer Ingelheim
• GSK
• Merck
• Novartis
• Roche
• Teva.

A company profile gives you the following information:
• Revenue forecast for asthma and COPD drugs from 2014 to 2024
• Discussion of a company’s activities and outlook
• Recent financial results
• Assessment of recent developments – mergers and acquisitions (M&A), new products, and collaborations, including alliances, partnerships and joint ventures

Discover capabilities, progress, and commercial prospects, helping you stay ahead.

Research and development – assess innovation, trends and possibilities
What about R&D – the pipeline for new drugs? You see trends for these areas:
• Bronchodilators
• Anti-inflammatory drugs
• Combination drugs
• Other progress in asthma and COPD.

Our study also discusses these agents and technologies, among others:
• Monoclonal antibodies
• Muscarinic antagonists and beta-agonists (MABAs)
• Once-daily combination products
• Triple combination therapies
• Generic combination drugs
• Other novel small molecules including CRTH2 inhibitors.

Novel compounds and new formulations with high safety, efficacy and affordability are in great demand. Our work explains, discussing many issues.

What issues will affect the asthma and COPD therapies industry?
Our new report discusses issues and events affecting the asthma and COPD therapies market. You will find discussions, including qualitative analyses:
• Increasing demand for asthma and COPD drugs due to increasing prevalence
• A strong anti-inflammatory drugs R&D pipeline
• Patent expiry and generic competition
• Growth areas such as monoclonal antibodies and once-daily combination drugs
• Pricing and reimbursement issues

You will see discussions of technological, commercial, and economic matters, with emphasis on the competitive landscape and business outlooks.

How the Asthma and COPD Therapies Market Forecast 2014-2024: Opportunities for Leading Companies report helps you
In summary, our 335-page report gives you the following knowledge:
• Revenue forecasts to 2024 for the world asthma and COPD therapies market and 3 product categories (therapeutic classes) – discover the industry’s prospects, finding promising places for investments and revenues
• Revenue forecasts to 2024 for the leading 12 national markets – US, Japan, China, Germany, France, UK, Italy, Spain, India, Brazil, Russia, Mexico and Rest of the World
• Assessment of 7 leading companies – hear about products, results and strategies including revenue forecasts for asthma and COPD drugs to 2024
• Predicted revenues of 27 leading drugs to 2024 – see potentials of top products
• Review of R&D pipelines – investigate developmental trends and progress
• Discussion of what stimulates and restrains companies and the market
• Prospects for established firms and those seeking to enter the market
• View opinions from our survey, seeing interviews with authorities

You will find quantitative and qualitative analyses with independent predictions. You will receive information that only our report contains, staying informed with this invaluable business intelligence.

Information found nowhere else
With our survey you are less likely to fall behind in knowledge or miss opportunity. See how you could benefit your research, analyses, and decisions. Also see how you can save time and receive recognition for commercial insight.

Visiongain’s study is for everybody needing commercial analyses for the asthma and COPD therapies market and leading companies. You find data, trends and predictions. Please order our report now.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

Download sample pages

Complete the form below to download your free sample pages for Asthma and COPD Therapies Market Forecast 2014-2024


Download sample pages

Complete the form below to download your free sample pages for Asthma and COPD Therapies Market Forecast 2014-2024


Connect with us

Visiongain Pharma

Visiongain Pharma

Visiongain Pharma

Latest Pharma news

Visiongain Publishes Direct-to-Patient Market Report 2021-2031

Over the last few years, Direct-to-Patient has gained widespread attention. DTP companies offer their customers, who are patients, in this case, all kinds of services.

21 July 2021

READ

Visiongain Publishes Drug Delivery Technologies Market Report 2021-2031

Rising geriatric population, increasing prevalence of chronic and infectious diseases, escalating investment in drug R&D by biopharmaceutical companies, rising demand for advanced drug delivery technologies for chronic treatment are some of the major factors that drive the growth of the global drug delivery technologies market.

20 July 2021

READ

Visiongain Publishes Pharma Contract Sales Market Report 2021-2031

Pharma services companies are widening their service offerings (either organically or inorganically through M&A) to become full-service providers, simplifying their customers’ operations and gaining the maximum share of their outsourcing budgets, driven by the willingness of pharma to reduce the number of outsourcers they use.

14 July 2021

READ

Visiongain Publishes Clinical Trial Supply and Logistics Market for Pharma 2021-2031

Digital innovation in clinical trials and renewed focus on home production will ensure a high growth market for supply chain optimisation.

12 July 2021

READ

Categories